Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ezetimibe (Ezetrol): the statins' partner].

J Ducobu1, J Sternon

  • 1Service de Médecine Interne, C.H.U. Tivoli, La Louvière.

Revue Medicale De Bruxelles
|December 9, 2004
PubMed
Summary

Ezetimibe effectively lowers LDL cholesterol by inhibiting intestinal absorption. Combined with statins, it enhances LDL reduction and helps patients reach cholesterol goals with a favorable safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

[Thyroid nodules: benign or malignant?].

Revue medicale de Bruxelles·2011
Same author

Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization.

Atherosclerosis·2011
Same author

[Pedagogy and clinical medicine].

Revue medicale de Bruxelles·2010
Same author

[New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?].

Revue medicale de Bruxelles·2010
Same author

[Place of fibrates for the treatment of patients with atherogenic dyslipidemia].

Revue medicale de Liege·2009

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Context:

  • Hyperlipidemia management requires effective LDL-C reduction.
  • Statins are first-line therapy but may not achieve target goals for all patients.

Purpose:

  • To evaluate the efficacy and safety of ezetimibe as a novel cholesterol absorption inhibitor.
  • To assess ezetimibe's role in monotherapy and in combination with statins for managing LDL-C levels.

Summary:

  • Ezetimibe selectively inhibits intestinal cholesterol absorption without impacting triglyceride, bile salt, or fat-soluble vitamin absorption.
  • Ezetimibe 10 mg/day monotherapy reduced LDL-C by approximately 18%.
  • Combination therapy with ezetimibe and statins achieved LDL-C lowering comparable to or exceeding high-dose statins alone, improving goal attainment.

Impact:

  • Ezetimibe offers a new therapeutic option for hyperlipidemia, particularly for patients not at their LDL-C goals with statins alone.
  • Combination therapy demonstrates synergistic effects, potentially reducing cardiovascular risk.
  • Ezetimibe exhibits a safety profile comparable to placebo or statins alone, with mild, asymptomatic aminotransferase increases and no rhabdomyolysis observed.

Related Experiment Videos